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Background: Macrophage migration inhibitory factor (MIF) is a widely expressed cytokine involved in a variety of
cellular processes including cell cycle regulation and the control of proliferation. Overexpression of MIF has been
reported in a number of cancer types and it has previously been shown that MIF is upregulated in melanocytic
tumours with the highest expression levels occurring in malignant melanoma. However, the clinical significance of
high MIF expression in melanoma has not been reported.
Methods: MIF expression was depleted in human melanoma cell lines using siRNA-mediated gene knockdown and
effects monitored using in vitro assays of proliferation, cell cycle, apoptosis, clonogenicity and Akt signalling. In silico
analyses of expression microarray data were used to correlate MIF expression levels in melanoma tumours with
overall patient survival using a univariate Cox regression model.
Results: Knockdown of MIF significantly decreased proliferation, increased apoptosis and decreased
anchorage-independent growth. Effects were associated with reduced numbers of cells entering S phase
concomitant with decreased cyclin D1 and CDK4 expression, increased p27 expression and decreased Akt
phosphorylation. Analysis of clinical outcome data showed that MIF expression levels in primary melanoma
were not associated with outcome (HR = 1.091, p = 0.892) whereas higher levels of MIF in metastatic lesions
were significantly associated with faster disease progression (HR = 2.946, p = 0.003 and HR = 4.600, p = 0.004, respectively
in two independent studies).
Conclusions: Our in vitro analyses show that MIF functions upstream of the PI3K/Akt pathway in human melanoma
cell lines. Moreover, depletion of MIF inhibited melanoma proliferation, viability and clonogenic capacity. Clinically, high
MIF levels in metastatic melanoma were found to be associated with faster disease recurrence. These findings support
the clinical significance of MIF signalling in melanoma and provide a strong rationale for both targeting and
monitoring MIF expression in clinical melanoma.
Keywords: Akt signalling, BRAF, Cell cycle, MIF, Melanoma, Metastasis, Prognostic factor, Proliferation* Correspondence: rick.thorne@newcastle.edu.au
2Hunter Medical Research Institute, New Lambton Heights, NSW 2305,
Australia
5School of Environmental and Life Sciences, Faculty of Science & IT,
University of Newcastle, Ourimbah, NSW 2258, Australia
Full list of author information is available at the end of the article
© 2014 Oliveira et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain
Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article,
unless otherwise stated.
Oliveira et al. BMC Cancer 2014, 14:630 Page 2 of 14
http://www.biomedcentral.com/1471-2407/14/630Background
Macrophage migration inhibitory factor (MIF), so named
because it inhibited the random migration of macrophages,
was first discovered as a cytokine product of T lymphocytes
[1,2]. It is now known that a variety of other cells types
produce MIF, including other immune cells, endocrine,
endothelial and epithelial cells [3,4]. High levels of MIF
have also been reported in vivo in several cancer types in-
cluding breast [5], lung [6] and gastric cancers [7] and the
work of several groups points to a correlation between
MIF expression and cancer prognosis, e.g. head and neck
cancer and glioblastoma [8-10]. Moreover, findings that
MIF is involved in critical pro-survival signalling pathways
together with cell cycle control has provided interest in
possible associations with the development and progres-
sion of cancer.
MIF protein is stored in pre-formed, cytoplasmic pools
and is rapidly released in response to stimuli such as mi-
crobial products, proliferative signals and hypoxia [3,4,11]
through a nonconventional ABC transporter pathway [12].
It is considered to be atypical of the conventional classes
of cytokines with known functions extended to roles as
both a hormone and an enzyme (reviewed in [3,13]). MIF
has also been shown to play a role in cell proliferation
where it has been suggested to be involved in the develop-
ment and progression of cancer, acting as an extracellular,
pro-tumourigenic factor [14,15].
The transmission of MIF signals occurs through a num-
ber of receptor systems, the first identified being the cell
surface receptor CD74 [16]. CD74 itself lacks intracellular
signalling domains [17] but it has been shown that CD44
acts as a co-receptor for CD74 to provide the means
whereby MIF signals are transmitted [18]. More recently,
the CXC chemokine receptors CXCR2 and CXCR4 were
also identified as MIF receptors and CD74 has also been
shown to form functional heteromeric receptor complexes
with CXCR2 and CXCR4 [19,20]. Depending on the cellu-
lar context, binding of MIF to its known cell surface recep-
tors can lead to activation of two fundamental signalling
axes, namely the mitogen-activated protein kinase (MAPK)
pathway and PI3K/Akt signalling [14,21-23]. In addition,
the cytoplasmic pool of MIF has also been shown to exert
other signalling actions.
MIF expression has also been shown to be of significance
in a limited number of studies investigating melanoma
biology. Higher levels of MIF mRNA were identified within
isogenic variants of the human A375 melanoma selected
for higher metastatic potential in nude mice [24]. Inhib-
ition of MIF expression in the G361 human melanoma
cell line resulted in inhibition of proliferation, migration
and tumour-induced angiogenesis [25]. MIF production
was also shown in human uveal melanoma cell lines
whereby MIF prevented their lysis by NK cells [26].
Additionally, in the B16-F10 mouse melanoma model,inhibition of MIF by RNAi significantly delayed tumour
establishment when injected into mice [27]. Collectively
these results implicate MIF in melanoma progression,
but despite this evidence, little is known on the down-
stream signalling pathways regulated by MIF signalling,
nor has this concept been evaluated in patient studies.
In the present study, we sought to establish the primary
downstream signalling pathways activated by MIF in a
panel of human melanoma cell lines in vitro using specific
knock-down studies and determine the prognostic signifi-
cance of MIF expression in metastatic melanoma. Our
data demonstrates that MIF is involved in melanoma pro-
liferation and anchorage-independent growth, mediated
through the activity of the PI3K/Akt pathway. We also es-
tablish that in clinical melanoma samples, MIF expression
increases with metastatic progression and is correlated
with survival for metastatic melanoma patients. Taken
together, these results highlight the importance of the
MIF-signalling axis with implications for targeted treat-
ment approaches in melanoma.
Methods
Cell culture
Human melanoma cell lines were cultured in Dulbecco’s
modified Eagle’s medium (DMEM; Lonza) supplemented
with 5% foetal bovine serum (FBS; Sigma-Aldrich) at 37°C
in a humidified atmosphere of 5% CO2. Me1007 and
MM200 were established from primary melanomas [28],
MelCV, MelRMu and MelFH were from lymph node me-
tastases [29] and MelRM was derived from a bowel metas-
tasis [29]. Melanoma cell lines with the prefix Mel were
isolated from fresh surgical biopsies from patients attend-
ing the Sydney and Newcastle Melanoma Units. Where
indicated, cell number and viability were estimated using
an ADAM-MC Automatic Cell Counter (Digital Bio). The
assay employs the propidium iodide (PI) method comparing
suspensions of PI-stained intact cells (measuring non-viable
cells) against PI-stained permeabilised cells (measuring total
cells). Cell suspensions were measured in triplicate for
each time point.
Western blotting
Cells were lysed using NDE lysis Buffer (1% Nonidet P-40,
0.4% sodium deoxycholate, 66 mM EDTA, 10 mM
Tris–HCl, pH 7.4) supplemented with protease and
phosphatase inhibitors (Complete protease inhibitor
mixture and PhosSTOP, respectively; Roche Applied
Science). Protein concentrations were quantitated using
BCA assay (Pierce) before electrophoresis on SDS-PAGE
gels. Western blotting detection using ECL was performed
as previously described [30] with bands visualized
using a cooled charge-coupled device camera system
(Fuji-LAS-4000, Fujifilm Life Science Systems). Primary
antibodies used were: MIF (MAB289; R&D Systems);
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spectively; Cell Signaling Technologies); cyclin D1 and
CDK4 (sc-20044 and sc-23896, respectively; Santa Cruz
Biotechnology); p27 (610242; BD Transduction Laboratories™)
and GAPDH (sc-25778; Santa Cruz). Secondary antibodies
used were horseradish peroxidise (HRP)-conjugated anti-
mouse or anti-rabbit (1706516 and 1706515 respectively;
BioRad Laboratories).Small interfering RNA
Cells were seeded into 6-well plates at 105 cells per well
and allowed to reach 30-40% confluency before trans-
fection. Synthetic siRNA duplexes were purchased from
Shanghai GenePharma (PRC). Targeting sequences and
validation experiments are shown in Additional file 1:
Figure S1. Cells were transfected at indicated concentrations
with siRNA duplexes using Lipofectamine™ RNAiMAX
(Invitrogen, #13778) according to manufacturer’s in-
structions. Efficiency of gene knockdown was assessed
by Western blotting.Flow cytometric analyses
DNA content analyses including quantitation of apoptotic
(sub-G1) cells were performed using the propidium iodide
(PI) staining method as described elsewhere [29]. The
Click-iT™ EdU flow cytometry assay (Invitrogen, #C35002)
was also used to determine the percentage of cells in S-
phase. Briefly, three days after transfection with siRNA,
cells were pulsed with 5-ethynyl-2′-deoxyuridine (EdU;
10 μM for 3 hours) before processing the cells according
to manufacturer’s instructions. Receptor expression studies
were performed using indirect immunostaining as previ-
ously described [31]. All flow cytometry was performed
using a FACS Calibur II instrument with analyses con-
ducted with either the Cell Quest software package v4
(Becton-Dickinson) or FlowJo v10.Soft agar colony formation
The ability of cells to grow under anchorage-independent
conditions was measured by a soft agar colony formation
assay. Briefly, 6 well plates were under-coated with 1 mL
of 0.6% low melting point agar (MetaPhor®) in DMEM.
Cells were harvested and 1×104 cells resuspended in 1 mL
of 0.3% agar/DMEM/10% FBS and the cell suspension
was poured on the bottom agar layer. Plates were then in-
cubated for 3–4 weeks before staining with 0.005% (w/v)
crystal violet to visualise colonies. Bright field photomicro-
graphs from random fields were collected using an Axiocam
MRm camera fitted to Axiovert 200 inverted microscope
(Zeiss) and these used to count colony frequencies. The
size of colonies was estimated using the Axiovision soft-
ware package (v4.8.1, Zeiss).In silico analyses
Publically available microarray gene expression data sets
were sourced from the NCBI gene expression omnibus
(GEO) database (http://www.ncbi.nlm.nih.gov/geo/) and
normalized data used to determine the relative levels of
genes of interest using methods previously described [32].
Where indicated, MIF expression was correlated with pa-
tient outcome whereby the primary end points for survival
analyses were disease-specific survival (measured from the
date of diagnosis to disease-specific death, or otherwise
censored at the time of the last follow-up or at non-
disease-related death). Time to disease-specific death
was plotted using Kaplan-Meier survival curves.
Results
Small interfering RNA knockdown of MIF decreases
melanoma cell proliferation and viability
We designed four individual siRNA oligonucleotide du-
plexes targeting MIF and determined the ability of each to
down-regulate cellular protein levels of MIF. Western
blotting analysis identified two sequences (MIF-21 and
MIF-25) that were effective in reducing MIF levels in mel-
anoma cell lines (Additional file 1: Figure S1A and B).
During the course of this work, another study targeting
MIF in lung cancer cells also demonstrated efficient
knockdown of MIF using duplexes identical to the
MIF-25 targeting sequence [33].
To determine the effects of MIF knockdown on melan-
oma cell growth, cell number and viability were measured
each day over a 5 day period. Comparison of MelCV and
Me1007 melanoma cells transfected with MIF-25 siRNAs
confirmed a substantial reduction in the total MIF protein
measured in cell lysates relative to negative control
(NC) siRNA treatment (Figure 1A and B, respectively).
For both cell lines, the total number of cells began to de-
crease after 3 days of MIF knockdown (Figure 1C and D)
and this was accompanied by significant reductions in cell
viability (Figure 1E and F). Both active siRNA duplexes
(MIF-21 and MIF-25) promoted equivalent biological re-
sponses (Additional file 1: Figure S1C and data not shown)
indicating that depletion of endogenous MIF can signifi-
cantly compromise the proliferative capacity and viability
of melanoma cells in culture.
MIF depletion retards melanoma cell cycle progression
and prevents anchorage-independent growth
To address the mechanism whereby MIF depletion was
associated with reduced cell growth and viability, DNA
contents were measured by flow cytometry. Representa-
tive profiles of MelCV and Me1007 cells are shown after
treatment with control NC siRNA or siRNA against MIF
(Figure 2A and B). As shown, MIF depletion resulted in
an increased number of cells in the G0/1-phase in both
cell lines (i.e. from 57% to 87% and 61% to 71% for
Figure 1 Small interfering RNA (siRNA) knockdown of MIF decreases melanoma cell proliferation and viability. Melanoma cell lines were
transfected with MIF siRNA duplexes (50 nM MIF-25) or negative control (NC) duplexes under the same conditions. Cellular MIF levels measured
in both (A) MelCV and (B) Me1007 cell lines using Western blot show sequential reductions in MIF protein after transfection that were sustained
for 4–5 days. Cell number and viability were determined in corresponding samples of MelCV (C and E respectively) and Me1007 (D and F, respectively).
Results show both MelCV and Me1007 showed a significant reduction in the cell number starting from day 3 after transfection with viability also
reduced in a time-dependent manner. Values are mean +/−SEM (n = 3, ****p < 0.0001; ***p < 0.001; **p < 0.01; *p < 0.05 comparing between NC and
MIF siRNA transfected cells using Student’s t-test).
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there was a reduction in the number of cells recorded in
the S- and G2/M phases after MIF depletion (Figure 2A)
while in Me1007 cells the major effect appeared to be a
reduction in the percentage of cells in S-phase (Figure 2B).
In addition to the changes in cell cycle parameters, we
also assessed whether cells were undergoing increased
rates of apoptosis as suggested by the decreased viability
observed in Figure 1. An estimate of apoptosis was de-
termined from the DNA content analysis as the number
of cells appearing in the sub-G0/1 region, i.e. cells with
DNA content of less than 2n. This analysis showed that
the basal level of apoptosis in control cultures increased~2-3 fold when the MelCV or Me1007 were treated with
siRNA against MIF for 3 days (Figure 2C and D). Taken
together with the results of Figure 1, these data suggest
that reduced cell growth occurred as a result of cells ac-
cumulating in the G0/1 phase and that the progressive
decline in cell viability was caused in part by increased
rates of apoptosis.
To better define the effects of MIF knock down in mel-
anoma cell lines, particularly their decreased proliferative
capacity, the ability of cells to enter the S-phase of the cell
cycle was measured using the Click-iT™ EdU flow cytome-
try assay. Click-iT analysis of MelCV and Me1007 cells
treated with MIF siRNA showed a clear reduction in cells
Figure 2 Effects of MIF knockdown on cell cycle and apoptosis. DNA content analysis using flow cytometry was performed on
(A) MelCV and (B) Me1007 cells after 3d of transfection with control (NC) or MIF siRNA duplexes. Representative profiles show the estimated percentages
of cells in gates representing G0/1 (G1), S and G2/M (G2) phases. Only cells with intact DNA contents (2n-4n) were analysed. Apoptotic rates
were also estimated as the percentage of total cells present in the sub-G0/G1 region. The percentage of apoptotic cells was estimated from
(C) MelCV and (D) Me1007 cells after 3d of transfection with MIF or control siRNA duplexes. The histograms represent the means +/−S.E.
M. from 3 replicates (***p < 0.001 and *p < 0.05 comparing between treatments using Student’s t-test). Similar results were obtained in
three independent experiments.
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independent experiments show that inhibition of MIF ex-
pression significantly reduces the percentage of cells in S
phase compared to negative control siRNA transfection
for both the MelCV and Me1007 melanoma cell lines
(Figure 3C and D, respectively). MIF depletion also signifi-
cantly reduced the number of cells entering S-phase in
four of six melanoma cell lines examined (Figure 3E) sug-
gesting the proliferative capacity of the majority of mela-
nomas have some degree of reliance on MIF expression.
In addition to altered cell proliferation, the ability of
cells to undergo anchorage-independent cell growth is
another hallmark of cancer. Loss of MIF expression in
MelCV and Me1007 melanoma cell lines resulted in
significantly less colonies in both cell lines compared
to controls (Figure 4A–D). Moreover, the coloniesformed after MIF knockdown were also significantly
smaller than controls (Figure 4E and F). Taken to-
gether, these results provide further evidence that MIF
expression regulates both cell cycle entry and the clo-
nogeneic capacity of melanoma cells in vitro.
As part of our studies we also sought to determine
whether the individual responses of cell lines to MIF could
be explained by expression of the known cellular receptors
for MIF that comprise CD74 and its co-receptor CD44,
along with the chemokine receptors CXCR2 and CXCR4.
Analysis by both Western blotting and flow cytometry
showed that all six melanoma lines expressed both CD44
and CXCR4 while none expressed CXCR2 (Additional file 1:
Figures S2 and S3). All lines varied in expression of CD74
but there was no clear correlation between expression levels
and sensitivity of individual cell lines to MIF depletion.
Figure 3 Effects of MIF knockdown on the S-phase of the cell cycle. The Click-iT™ EdU flow cytometry assay was used to measure the
numbers of cells entering S-phase over a 3 h period. Dual parameter plots compare cellular DNA content (7AAD) against Edu incorporation with
S-phase cells denoted by the inset box in each plot. Representative analyses for (A) MelCV and (B) Me1007 cells are presented after 3d of
transfection with control (NC) or MIF siRNA duplexes. Quantitation of the percentage of cells in S phase in (C) MelCV and (D) Me1007 cell lines
after MIF knockdown or treatment with control siRNA duplexes. (E) Analyses in (C) and (D) were repeated for an additional 4 melanoma cell lines.
Values shown represent the proportion of cells entering S phase after MIF siRNA treatment normalised against NC siRNA treatment. MIF depletion
significantly reduced the number of cells entering S-phase for 4/6 cell lines (means +/−S.E.M. from 5 independent experiments, ***p < 0.001
**p < 0.01 *p < 0.05 comparing between treatments using Student’s t-test).
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V600E BRAF status of each line and sensitivity to MIF de-
pletion since the V600E BRAF positive cell lines MelCV
and MelRMu were amongst the most sensitive to MIF de-
pletion (refer Discussion).MIF regulates PI3K/Akt signalling and key cell cycle
proteins in melanoma cell lines
Having established that MIF exerts effects on the cell cycle
entry and the clonogenic capacity of melanoma cells,
we sought to determine which pathways are activated
Figure 4 MIF knockdown decreases anchorage-independent colony formation. Three days after transfection using siRNA duplexes,
melanoma cells were harvested and seeded into soft agar and permitted to form colonies according to the Methods. Representative low power
photomicrographs demonstrating the relative abundance of colonies formed by (A) MelCV and (B) Me1007 cells after control NC or MIF siRNA
knockdown (the insets show colonies in detail under higher magnification). The frequency and size of colonies were then estimated for MelCV
(C) (E), respectively and Me1007 (D) (F), respectively where there was a significant reduction in colony numbers and size after MIF knockdown.
Values are mean +/−S.E.M. (n = 3, ****p < 0.0001 compared to siNC transfected cells using Student’s t-test).
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pathway is well established to play an important role in
melanoma progression [34-36] but to date no link has
been made between MIF expression and regulation of
the PI3K/Akt pathway in this setting. Therefore, we ex-
amined the effects of MIF knockdown on the expres-
sion of key Akt-signalling components in melanoma
cells. With respect to the proliferative capacity of mel-
anoma cells, it was observed from Figure 3 that four
melanoma cell lines tested were sensitive to MIF deple-
tion (MelCV, Me1007, MelRMu and MelFH) and an-
other two (MelRM and MM200) were comparatively
resistant. All six melanoma cell lines were subjected to
treatment with MIF siRNA with knockdown of MIF pro-
tein after three days of transfection confirmed relative tocontrols using Western blotting (Figure 5A). Analysis of
Akt phosphorylation status in cell lysates indicated a
strong reduction in MelCV, Me1007 and MelRMu cells
(~40-70% of controls) as a consequence of MIF knock-
down with a lesser reduction observed in MelFH, MM200
and MelRM cell lines (~20% of controls; Figure 5A).
We then sought to determine whether there was a direct
correlation between the relative effects of MIF knockdown
on cell proliferation (inhibition of S phase; Figure 3E) and
the relative levels of Akt activation for each cell line. There
was a demonstrable positive correlation where cell lines
most sensitive to MIF depletion also had the greatest
change in Akt activity and vice versa (Figure 5B). Further
analysis of the downstream cell cycle modulators known
to be influenced by Akt signalling was also undertaken.
Figure 5 MIF modulates the PI3K/Akt signalling pathway in melanoma cell lines. MIF expression was depleted in a panel of six melanoma
cell lines as described before. Three days after transfection, the cellular levels of MIF, Akt and key cell cycle regulators were measured using
Western blotting. Densitometric signals were calculated for each protein band using the MultiGauge software package (Fuji Life Sciences) and
used to determine relative expression following depletion of MIF. (A) Representative Western blots showing specific immunoreactive bands for
MIF in the indicated melanoma cell lines. The normalised ratio of expression of MIF was determined by dividing MIF levels after depletion against
control levels. (B) Levels of phosphorylated Akt (Ser 473) and total Akt where the ratio represents the relative phospho-Akt levels compared to
total Akt. (C) Levels of the cell cycle regulators cyclin D1, CDK4 and the cyclin-dependent kinase inhibitor p27. Each ratio was determined by
dividing the optical density of the specific band by the GAPDH value. The results shown were consistent across at least 3 independent
experiments. (D) Dual parameter plot comparing the degree of inhibition of proliferation after MIF knockdown (effects on the proportion of cells
entering S-phase; Figure 3) with the corresponding effects on the level of Akt activity observed (relative levels of pAkt; Figure 4A).
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showed some level of inhibition across the six cell lines,
whereas the expression of cyclin-dependent kinase inhibi-
tor, p27, was relatively increased in most of the cell lines
following MIF depletion. On balance these results support
the notion that Akt-signalling is down-regulated in re-
sponse to MIF knockdown with the degree of sensitivity
to MIF depletion commensurate with the inhibitory ef-
fects observed on the Akt pathway.
Expression levels of MIF in melanoma metastases are
associated with disease progression
After establishing that MIF expression is important for
the maintenance of melanoma cells in vitro, we investi-
gated whether MIF expression levels were also elevated
and/or associated with clinical outcomes in melanoma.
Firstly, we independently performed in silico analyses of
expression microarray data comparing the relative tran-
script levels of MIF in staged melanoma against normal
skin and naevi (samples of normal skin, benign naevi,
atypical naevi, melanoma in situ, vertical growth phase
(VGP) and metastatic growth phase (MGP) melanoma,
melanoma-positive lymph nodes (LN); deposited as
GEO dataset GSE4587 [37]). The expression levels ofMIF were determined as normalized intensity values
(GeneSpring 7.1, Silicon Genetics) for each sample
(Figure 6A). The level and pattern of MIF expression
show a general increase in MIF levels associated with
disease progression. Dividing the samples into two groups,
“early stage” (normal skin, benign and atypical naevi,
melanoma in situ) and “advanced stage” (VGP and MGP
melanomas, LN) demonstrated a statistically significant
increase in MIF expression in “advanced-stage” tissue
samples compared to the “early-stage” group (Figure 6B).
To substantiate this finding, further analyses were con-
ducted on the data set generated by Xu et al. [38] consist-
ing of eighty-three fresh biopsies from melanoma patients
(profiled using the Affymetrix U133A microarray plat-
form; GEO accession number GSE8401). The distribution
of MIF expression for primary melanoma (n = 31) and
metastatic melanoma (n = 52) are shown in Figure 6C and
D, respectively, where MIF mRNA levels appear relatively
increased in metastatic samples. Analysis of average levels
in each group showed a statistically higher level of MIF in
metastatic melanoma compared to primary tumour sam-
ples (Figure 6E). Collectively these findings support the
notion that MIF expression is up-regulated during melan-
oma progression.
Figure 6 MIF expression increases during progression of melanocytic lesions to advanced stage melanoma. (A) Levels of MIF mRNA
expression are compared in two normal skin tissue samples (NS1; NS2), benign naevi (BN1; BN2), atypical naevi (AN1; AN2), melanomas in situ (in
situ1; in situ2), VGP melanomas (VGP1; VGP2), MGP melanomas (MGP1; MGP2), and the three MGP melanoma-positive lymph nodes (LN1; LN2;
LN3). Data represent normalised levels extracted from GEO dataset GSE4587. (B) Average MIF expression levels were higher in “advanced stage”
samples compared to the “early stage” samples (mean +/−S.E.M. of early stage (n = 8) and advanced stage (n = 7) from (A), **p < 0.01 using the
Mann–Whitney test). (C/D) Frequency distribution histograms of MIF transcript expression in tissues of primary melanoma or metastatic melanoma.
Analyses were conducted on expression microarray data (GEO dataset GSE8401) from melanoma tissues of patients with progressive disease collected
as 31 cases of primary melanoma (C) and 52 cases of metastatic melanoma (D). (E) Analysis of MIF expression data from (C) and (D) shows the levels
are higher in metastatic melanoma compared to primary melanoma samples. (Values are mean +/−S.E.M. from primary and metastatic melanoma
cases respectively, **p < 0.01 using the Mann–Whitney test).
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pression in melanoma were predictive of outcome by
exploiting expression microarray data associated with clin-
ical outcomes. Since the levels of MIF differed between
primary and metastatic melanoma, analyses were con-
ducted on each classification where tumour biopsies were
initially segregated into quartiles of MIF expression ran-
ging from low to high values. Kaplan-Meir plots of MIF
levels against survival appeared to show no predictive sig-
nificance of MIF levels in primary melanoma tumours
(Figure 7A) whereas a clear trend was evident for meta-
static samples where the first and second quartiles segre-
gated from the third and fourth quartiles (Figure 7B).
Further analysis of the data using a 50% cut-off showed
that high levels of MIF in metastatic disease conferred sig-
nificantly poorer outcome compared to those tumours ex-
pressing lower levels of MIF mRNA (univariate Cox
regression; hazard ratio = 2.946; 95% confidence interval
1.440-6.029; p = 0.003; Figure 7C). The same analyses
conducted on the primary melanoma data showed nosignificant relationship between MIF expression in and
survival (hazard ratio = 1.091; 95% confidence interval
0.312-3.809; p = 0.892). As further validation, the same
analysis of an independent dataset of metastatic melan-
oma tissues (GSE19234; [39]) also indicated signifi-
cantly worse outcomes for patients whose tumours
expressed higher levels of MIF (univariate Cox regression;
hazard ratio = 4.600; 95% confidence interval 1.6-12.9;
p = 0.004; Figure 7D). Thus in patients where metastasis
had already occurred, those cases with tumours displaying
the highest levels of MIF progressed faster.
Discussion
To date, apart from two studies each using a single cell
line [24,25] the role of MIF in the context of human cu-
taneous melanoma has not been intensively studied. In
the present report we adopted an siRNA-based strategy
to examine the function of endogenous MIF expression
in multiple human melanoma cell lines. In MelCV and
Me1007 cell lines, MIF knockdown resulted in significantly
Figure 7 High MIF expression in metastatic melanoma lesions is associated with worse outcomes. Kaplan-Meier survival curves generated
on the basis of quartiles of MIF tumour expression levels in (A) primary and (B) metastatic melanoma tissues correlated against disease-specific
survival (GSE8401 dataset). (C) Kaplan-Meier survival curves generated for low and high expressing samples of metastatic melanoma tissues using
a 50% cutoff level (GSE8401 dataset). (D) Analysis conducted as per (C) on an independent dataset of metastatic melanoma tissues (GSE19234,
n = 38 cases).
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that endogenous MIF expression could be generally re-
quired for the growth of melanoma cells. The reduced
cell numbers corresponded to the increased accumula-
tion of cells in G0/1 and a decrease of cells in S-phase.
Moreover, accounting for the successive reduction in
the number of viable cells during the experiment, there
was an increased proportion of apoptotic cells following
MIF depletion. Similar findings were also obtained when
considering anchorage-independent growth where it
was shown that MIF siRNA transfection significantly
compromised the number and size of colonies formed
by melanoma cells.
To better understand the role of MIF expression in
melanoma cells, further quantitative assays were employedon six different melanoma cell lines. Cell proliferation
after MIF knockdown was further explored using the
Click-iT assay, a sensitive and quantitative assay which
measures the cell cycle. In particular the assay provides
an accurate measure of the number of cells entering S-
phase in a fixed time period. This analysis showed that
MIF knockdown significantly reduced cells transitioning
to the S-phase in four of the six melanoma cell lines
suggesting the proliferative capacity of the majority of
the melanoma cell lines studied have some degree of re-
liance on MIF expression. In agreement with these find-
ings, work from several authors have shown that MIF is
involved in cell cycle regulation in different cancer cells
[14,23,40], and MIF knockdown can cause G1 arrest by
inhibiting G1/S transition [41]. At least for the MelCV
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was clearly cytostatic but also compromised cell viability.
Collectively this reinforces the idea that MIF signalling
displays potential as a pathway that could be targeted for
melanoma treatment.
Leading on from these findings the question is raised
as to how MIF functions in this setting. We could not
establish that the sensitivity of individual melanoma cell
lines to MIF depletion resulted from the differential ex-
pression of known MIF receptors (i.e. CD74/CD44 and/or
CXCR4). We also considered the responsiveness of cells
lines in the context of known downstream signalling path-
ways. It is well established that MIF function is associated
with two major pro-survival pathways, namely the MAPK
and PI3K/Akt signalling pathways, each known to be im-
portant in melanoma. Indeed, oncogenic MAPK signalling
through ERK (RAS-RAF-MEK-ERK) is constitutively acti-
vated in the majority of melanomas [42,43] with aberrant
activation frequently stemming from activating mutations
in BRAF. Of these, the most common BRAF mutation
occurring in ~50% of all melanomas comprises a glutamic
acid to valine substitution at position 600 (V600E) [43-45].
Pharmacological inhibition of the RAF/MEK/ERK pathway,
in particular, via inhibition of mutated and activated BRAF,
has therefore appeared as a promising strategy for treatment.
This has led to the development of mutant-BRAF-specific
inhibitors [46-49] that have shown promising results in
clinical trials [47,50,51]. In our study, of the melanoma cell
lines tested for the effects of MIF inhibition, three express
wildtype BRAF (Me1007, MelRM and MelFH) while the
others bear the BRAF V600E mutation (MelCV, MelRMu
and MM200 [52]). Two of the three lines most sensitive
to MIF depletion are BRAF mutants (MelCV and MelRMu)
indicating the effects of MIF signalling in melanoma were
likely outside this pathway. This observation has important
therapeutic implications in patients that are resistant to
mutant BRAF inhibitors (e.g. [53]) whereby MIF depletion/
targeting could be used as an alternative strategy.
Alongside the MAPK pathway, constitutive activation
of the PI3K/Akt pathway is also important in a high pro-
portion of melanoma cases [54-56]. Such activation is
frequently associated with down-regulation or loss of
PTEN phosphatase that antagonises PI3K signalling. Ab-
sent or decreased PTEN expression occurs in up to 90%
of primary melanomas with mutations of PTEN or loss
of heterozygosity at the PTEN locus accounting for this
deficiency [57,58]. Transcriptional repression of the gene
by promoter methylation also occurs in a high propor-
tion of metastatic melanomas [59,60]. In addition to
PTEN, other major elements of the PI3K/Akt pathway
are found to be amplified or mutated in melanoma.
Akt3 expression is increased as a result of elevated gene
copy number in ~50% and ~70% of primary melanomas
and metastatic melanomas, respectively [36]. PI3K/Aktpathway activation in melanoma can also occur through
mutational activation of PI3KCA along with the muta-
tional activation of upstream receptor tyrosine kinases
such as c-KIT and EGFR [61,62]. Given the previous
links established between MIF and Akt signalling as de-
scribed in the Introduction, we focussed our efforts on in-
vestigating Akt as the likely major pathway downstream of
MIF in melanoma.
Akt activation can stimulate proliferation through mul-
tiple downstream targets that affect cell-cycle regulation
[63]. For example, Akt can phosphorylate p27 (Kip1)
cyclin-dependent kinase inhibitor, preventing its localisa-
tion to the nucleus and attenuating its cell-cycle inhibitory
effects [64-66]. In addition, Akt also serves to phosphoryl-
ate and inactivate GSK3. As GSK3 phosphorylates cyclin
D and cyclin E and targets them for proteasomal degrad-
ation [67,68], inhibition of GSK3 by Akt thereby acts to
stabilise key cyclins involved in cell cycle entry. In the
current study, MIF knockdown resulted in decreased Akt
phosphorylation in all melanoma cell lines tested, albeit to
varying degrees. This effect was accompanied by a reduc-
tion in expression of cyclin D1 and cyclin dependent kinase
4 (CDK4), and an increased expression of p27. Moreover
there was a correlation between the effects of MIF knock-
down and the degree of Akt activation amongst individual
cell lines. Collectively this suggests that activation of the
Akt pathway is one of the major mechanisms whereby
MIF contributes to cell cycle regulation in melanoma.
Since the overall importance of the PI3K/Akt pathway to
melanoma biology cannot be understated, these findings
imply clinical significance of MIF signalling in this disease.
Supporting this notion, a previous study of melanocytic
tumours showed MIF mRNA and protein levels were high
in malignant tumours while expression was significantly
lower in benign naevi [69]. Here we verified these data
using independent expression microarray datasets where
collectively these findings support the general concept that
MIF is differentially expressed between non-malignant
and malignant lesions with increased expression during
melanoma progression. Despite these observations and
previous work associating increased MIF with enhanced
melanoma growth and metastasis in nude mice [24], the
clinical significance of MIF tumour levels has surprisingly
not been previously examined. Our in silico analyses of
GEO datasets now reveal significant correlations between
MIF expression and patient outcome. While MIF levels in
primary tumours had no bearing on patient outcomes there
was a clear indication that high MIF expression levels in
metastatic lesions were significantly associated with shorter
survival times. Indeed, in the GSE19234 cohort, ~70% of
patients whose tumours has lower MIF expression remained
alive approaching 40 months of clinical follow-up.
One caveat to consider when linking our in vitro find-
ings to the clinical setting is the inherent complexity of
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pression in melanoma cells has an impact upon their
proliferative capacity in vivo but whether the MIF gene
expression detected in clinical samples is wholly tumour
derived is not entirely clear. Tumour tissue comprises a
non-homogenous mixture of tumour and stromal cells
including variable amounts of infiltrating immune cells.
In breast cancer, MIF is expressed in both tumour cells and
stromal cells, including tumour-associated macrophages
[5]. Indeed, MIF is a key cytokine in both innate and adap-
tive immune cells [3,4] and thus infiltrating immune cells
must also be considered as an intra-tumoural source of
MIF. Some breast cancer cells respond to exogenous MIF
by triggering a massive burst of MIF secretion suggesting
auto- or paracrine regulation of MIF [70]. Finally, it is
already well established that interactions between the
tumour and its microenvironment play an important
role in influencing the behaviour of tumour cells. Again
in breast cancer, it was found that MIF was highly up-
regulated in tumours cells when they were co-cultured
with macrophages. In turn, increased MIF secretion by
tumour cells contributed to metalloproteinase production
by the macrophages and this augmented the invasive po-
tential of the tumour cells [70]. Similarly it is known that
tumour-associated macrophages can enhance melanoma
growth though secreted factors (e.g. [71]) and equally
there are other infiltrating cells such as lymphocytes [72]
which are also potential sources of MIF. However the rela-
tive importance of MIF production in melanoma tumour
cells versus stromal cells remains to be established.Conclusions
Our results establish the concept that high MIF expression
levels in metastatic melanoma is associated with faster re-
lapse and death. Through in vitro analyses, a mechanism
in suggested where MIF expression is associated with acti-
vation of Akt signalling and promotion of melanoma pro-
liferation and survival. In the current environment where
mutant BRAF status dominates the clinical approach, the
effects of MIF signalling are notionally independent of
BRAF mutational status. Thus, in addition to the potential
of MIF as a prognostic marker, these data highlight the po-
tential utility for MIF and its signalling axis as a treatment
target in this disease.Additional file
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